Patents by Inventor Jerry Ryan Holder
Jerry Ryan Holder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240084301Abstract: The present application relates to compositions and methods for modulating expression of Family with Sequence Similarity 13 Member A (FAM13A) protein. In particular, the present application relates to nucleic acid-based therapeutics for reducing FAM13A gene expression via RNA interference and methods of using such nucleic acid-based therapeutics to reduce abdominal adiposity, reduce body weight, reduce fat mass, improve metabolic parameters including insulin resistance and non-alcoholic steatohepatitis (NASH), and reduce risk of myocardial infarction.Type: ApplicationFiled: July 24, 2023Publication date: March 14, 2024Applicant: AMGEN INC.Inventors: Elizabeth Ann KILLION, Jerry Ryan HOLDER, Bryan MEADE, Justin K. MURRAY, Oliver R. HOMANN, Briana Renee GRIEGO, Murielle Marie VENIANT ELLISON
-
Patent number: 11807693Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.Type: GrantFiled: January 28, 2021Date of Patent: November 7, 2023Assignee: AMGEN INC.Inventors: Jerry Ryan Holder, Gayathri Swaminath, Michael J. Frohn, Brian Alan Lanman, Anthony B. Reed, Leslie P. Miranda, John Gordon Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
-
Publication number: 20210261619Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.Type: ApplicationFiled: January 28, 2021Publication date: August 26, 2021Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Michael J. FROHN, Brian Alan LANMAN, Anthony B. REED, Leslie P. MIRANDA, John Gordon ALLEN, Alexander J. PICKRELL, Aaron C. SIEGMUND, Lewis D. PENNINGTON, Bryant YANG
-
Publication number: 20210154318Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.Type: ApplicationFiled: January 15, 2021Publication date: May 27, 2021Inventors: Yuan CHENG, Chawita NETIROJJANAKUL, Jerry Ryan HOLDER, Bin WU, James R. FALSEY, Bradley J. HERBERICH, Kelvin SHAM, Leslie P. MIRANDA, Shu-Chen LU, Murielle VENIENT-ELLISON, Shanaka STANISLAUS, Junming YIE, Jing XU
-
Patent number: 10941182Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.Type: GrantFiled: June 10, 2015Date of Patent: March 9, 2021Assignee: Amgen Inc.Inventors: Jerry Ryan Holder, Gayathri Swaminath, Michael J. Frohn, Brian Alan Lanman, Anthony B. Reed, Leslie P. Miranda, John G. Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
-
Patent number: 10905772Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.Type: GrantFiled: January 16, 2018Date of Patent: February 2, 2021Assignee: Amgen Inc.Inventors: Yuan Cheng, Chawita Netirojjanakul, Jerry Ryan Holder, Bin Wu, James R. Falsey, Bradley J. Herberich, Kelvin Sham, Leslie P. Miranda, Shu-Chen Lu, Murielle M. Veniant-Ellison, Shanaka Stanislaus, Junming Yie, Jing Xu
-
Publication number: 20200384119Abstract: Method of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.Type: ApplicationFiled: June 20, 2018Publication date: December 10, 2020Applicant: AMGEN INC.Inventors: Kenneth W. WALKER, Jerry Ryan HOLDER, David J. LLOYD, Shu-Chen LU, MurIelle M. VENIANT-ELLISON, Shanaka STANISLAUS
-
Patent number: 10344060Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: March 12, 2014Date of Patent: July 9, 2019Assignee: AMGEN INC.Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda, Kaustav Biswas, Bin Wu, Kelvin Sham, Jason C. Long
-
Publication number: 20180311372Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.Type: ApplicationFiled: January 16, 2018Publication date: November 1, 2018Applicant: AMGEN INC.Inventors: Yuan CHENG, Chawita NETIROJJANAKUL, Jerry Ryan HOLDER, Bin WU, James R. FALSEY, Bradley J. HERBERICH, Kelvin SHAM, Leslie P. MIRANDA, Shu-Chen LU, Murielle VENIANT-ELLISON, Shanaka STANISLAUS, Junming YIE, Jing XU
-
Patent number: 9636418Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: March 12, 2014Date of Patent: May 2, 2017Assignee: AMGEN INC.Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda
-
Publication number: 20170107255Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.Type: ApplicationFiled: June 10, 2015Publication date: April 20, 2017Applicant: AMGEN INC.Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Michael J. FROHN, Brian Alan LANMAN, Anthony B. REED, Leslie P. Miranda, John G. Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
-
Publication number: 20160067347Abstract: The application is directed to APJ receptor agonist analogs having increased stability relative to the wild type apelin-13 and methods of using the agonist analogs. The analogs can be used, inter alia, in cardiac disorders such as heart failure.Type: ApplicationFiled: December 17, 2013Publication date: March 10, 2016Applicant: AMGEN INC.Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Leslie P. MIRANDA, Jennifer ARAL, Elizabeth M. DOHERTY, Thomas NIXEY
-
Publication number: 20160024159Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: January 28, 2016Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA, Kaustav BISWAS, Bin WU, Kelvin SHAM, Jason C. LONG
-
Publication number: 20150023988Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: January 22, 2015Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA
-
Patent number: 8168592Abstract: Disclosed is a composition of matter that involves a CGRP peptide antagonist. A pharmaceutical composition is disclosed that comprises the composition of matter and a pharmaceutically acceptable carrier, which can be configured for administration to a patient. Also disclosed is a method of producing the composition of matter. Methods of treating, preventing or mitigating migraine, are also disclosed.Type: GrantFiled: October 19, 2006Date of Patent: May 1, 2012Assignee: Amgen Inc.Inventors: Colin V. Gegg, Jr., Eileen J. Johnson, Leslie P. Miranda, Kenneth W. Walker, Jerry Ryan Holder, Marie E. Wright, Derin C. D'Amico
-
Patent number: 7368433Abstract: The subject invention provides novel peptides for use in treating mammals to control appetite and obesity. Disclosed is a peptide derivative having the formula: X1-Z-Q-arg-trp-NH2 wherein: X1 is an acyl group, Z is amino-2-naphthyl-carboxylic acid or histidine, Q is (D)phenylalanine or p-iodo-(D)phenylalanine, or a pharmacologically acceptable salt, complex or derivative thereof, the peptide derivative having melanocortin-4 receptor agonist activity.Type: GrantFiled: November 8, 2005Date of Patent: May 6, 2008Assignee: University of Florida Research Foundation, Inc.Inventors: Carrie Haskell-Luevano, Jerry Ryan Holder
-
Patent number: 7034004Abstract: The subject invention provides novel peptides for use in treating mammals to control appetite and obesity. Disclosed is a peptide derivative having the formula: X1-Z-Q-arg-trp-NH12 wherein: X1 is an acyl group, Z is amino-2-naphthyl-carboxylic acid or histidine, Q is (D)phenylalanine or p-iodo-(D)phenylalanine, or a pharmacologically acceptable salt, complex or derivative thereof, the peptide derivative having melanocortin-4 receptor agonist activity.Type: GrantFiled: May 7, 2002Date of Patent: April 25, 2006Assignee: University of FloridaInventors: Carrie Haskell-Luevano, Jerry Ryan Holder